AstraZeneca : AZN

All AstraZeneca Articles

218 Articles

Jon C. Ogg | Oct 20, 2015 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Bluebird Bio, Boston Beer, Etsy, Gilead, Pfizer, PMC-Sierra, Valeant and More

Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.

Jon C. Ogg | Sep 14, 2015 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: AeroVironment, Gold Fields, Marvell, Nokia, Silver Wheaton and Many More

Monday's top analyst upgrades, downgrades and initiations include AeroVironment, Gold Fields, Marvell Technology, Nokia and Silver Wheaton.

Jon C. Ogg | Sep 2, 2015 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: ARM, AT&T, Hasbro, Lending Club, PNC, Vodafone, Disney and Many More

Wednesday’s top analyst upgrades, downgrades and initiations include ARM Holdings, AT&T, Hasbro, Lending Club, PNC Financial Services, Vodafone and Walt…

Lee Jackson | May 22, 2015 at 9:15 AM EDT

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug…

Chris Lange | Feb 5, 2015 at 10:10 AM EST

Are Teva’s Earnings Good Enough?

Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.

Jon C. Ogg | Jan 26, 2015 at 4:53 PM EST

Is a Generic Nexium Purple Pill for You?

Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United…

Jon C. Ogg | Sep 23, 2014 at 1:30 PM EDT

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have…

Paul Ausick | Jul 29, 2014 at 7:50 AM EDT

Drugmakers Merck, Pfizer Eke Out Profit Hikes

Drug giants Merck and Pfizer reported better-than-expected second-quarter 2014 results before markets opened Tuesday morning.

Jon C. Ogg | May 27, 2014 at 1:35 PM EDT

Pfizer’s Real Issue: Identity Crisis Against Peers

Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance…

Jon C. Ogg | May 27, 2014 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: AMC, Cisco, NextEra, NRG, Staples and More

These are the top Wall Street analyst upgrades, downgrades and initiations seen after the three-day Memorial Day weekend. They include…

Douglas A. McIntyre | May 19, 2014 at 3:11 PM EDT

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

ThinkstockBig news from two of the market’s biggest names is making waves across Wall Street today as stocks advance through a…

Paul Ausick | May 6, 2014 at 11:05 AM EDT

Cross-Border Premium Implications in Merck-Bayer Transaction

Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced…

Paul Ausick | May 5, 2014 at 8:00 AM EDT

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower…

Paul Ausick | May 2, 2014 at 8:55 AM EDT

AstraZeneca Declares Pfizer Bid ‘Inadequate’

British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion…

Jon C. Ogg | Apr 22, 2014 at 8:35 AM EDT

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick…

1 … 7 8 9 10 11 … 15

AstraZeneca : AZN

All AstraZeneca Articles

Top Analyst Upgrades and Downgrades: Bluebird Bio, Boston Beer, Etsy, Gilead, Pfizer, PMC-Sierra, Valeant and More

Top Analyst Upgrades and Downgrades: AeroVironment, Gold Fields, Marvell, Nokia, Silver Wheaton and Many More

Top Analyst Upgrades and Downgrades: ARM, AT&T, Hasbro, Lending Club, PNC, Vodafone, Disney and Many More

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

Are Teva’s Earnings Good Enough?

Is a Generic Nexium Purple Pill for You?

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

Drugmakers Merck, Pfizer Eke Out Profit Hikes

Pfizer’s Real Issue: Identity Crisis Against Peers

Top Analyst Upgrades and Downgrades: AMC, Cisco, NextEra, NRG, Staples and More

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

Cross-Border Premium Implications in Merck-Bayer Transaction

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

AstraZeneca Declares Pfizer Bid ‘Inadequate’

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

AstraZeneca : AZN

All AstraZeneca Articles

Top Analyst Upgrades and Downgrades: Bluebird Bio, Boston Beer, Etsy, Gilead, Pfizer, PMC-Sierra, Valeant and More

Top Analyst Upgrades and Downgrades: AeroVironment, Gold Fields, Marvell, Nokia, Silver Wheaton and Many More

Top Analyst Upgrades and Downgrades: ARM, AT&T, Hasbro, Lending Club, PNC, Vodafone, Disney and Many More

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

Are Teva’s Earnings Good Enough?

Is a Generic Nexium Purple Pill for You?

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

Drugmakers Merck, Pfizer Eke Out Profit Hikes

Pfizer’s Real Issue: Identity Crisis Against Peers

Top Analyst Upgrades and Downgrades: AMC, Cisco, NextEra, NRG, Staples and More

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

Cross-Border Premium Implications in Merck-Bayer Transaction

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

AstraZeneca Declares Pfizer Bid ‘Inadequate’

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not